Endometriosis in the setting of Muckle-Wells syndrome treated with an IL-1β antagonist

Natsuko Sasaki-Saito, Sasaki-Saito N, Yu Sawada, Sawada Y, Ohmori S, Shun Ohmori, Omoto D, Daisuke Omoto, Sanehito Haruyama, Haruyama S, Yoshioka M, Manabu Yoshioka, Nishio D, Daisuke Nishio, Nakamura M, Motonobu Nakamura
European journal of dermatology : EJD · 2017 · vol. 27(4) , pp. 442–443 · doi:10.1684/ejd.2017.3052 · PMID:28508753 · W2739197276
Case report OA: closed CC0 ⤵ 1 in-corpus citation
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-06-11 ⓘ

This case report describes endometriosis in a patient with Muckle-Wells syndrome treated with an IL-1β antagonist.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-11 · read from full text ⓘ

The paper describes endometriosis occurring in a patient with Muckle-Wells syndrome, a form of cryopyrin-associated autoinflammatory syndrome due to heterozygous NLRP3 (CIAS) mutations, and reports treatment with an interleukin-1β (IL-1β) antagonist. It provides a clinical narrative framed by the broader context that IL-1 antagonists are being used as therapy in autoinflammatory conditions, but it does not present a controlled study design. A key caveat is that the work is limited to a small case-based discussion rather than systematic, generalizable evidence. This paper is centrally about endometriosis—specifically endometriosis developing in the setting of Muckle-Wells syndrome and treated with an IL-1β antagonist.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,005 characters · extracted from oa-doi-fallback · click to expand
European Journal of Dermatology MENUEndometriosis in the setting of Muckle-Wells syndrome treated with an IL-1β antagonist Volume 27, numéro 4, July-August 2017 Illustrations Department of Dermatology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan - DOI : 10.1684/ejd.2017.3052 - Page(s) : 442-3 - Année de parution : 2017 Cryopyrin-associated autoinflammatory syndrome (CIAS) is characterized by a triad of rash, arthropathy, and central nervous system involvement [1]. Chronic infantile neurological cutaneous articular syndrome (CINCA), Muckle-Wells syndrome, and familial cold autoinflammatory syndrome have been shown to be allelic, caused by heterozygous mutations in the CIAS gene, NLPR3, on chromosome 1q44, which encodes a pyrin-like protein [2]. Interleukin (IL)-1 antagonists are emerging as an effective therapy [...]

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Cryopyrin-Associated Periodic Syndromes Cryopyrin-Associated Periodic Syndromes Endometriosis Interleukin-1beta Interleukin 1 Receptor Antagonist Protein Cryopyrin-Associated Periodic Syndromes Cryopyrin-Associated Periodic Syndromes Endometriosis Endometriosis Endometriosis Female Female Humans Humans Interleukin-1beta Interleukin-1beta Interleukin-1beta Interleukin 1 Receptor Antagonist Protein Interleukin 1 Receptor Antagonist Protein Middle Aged

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

Cited by (1)

References (6)

Cited by (1)

Source provenance

europepmc
last seen: 2026-10-17T06:09:56.316927+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:19:54.474666+00:00
unpaywall
last seen: 2026-10-17T06:24:38.187582+00:00
License: CC0 · commercial use OK